Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 9/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 8/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 7/20 | 0.33 |
| ▸ | TYK2 | P29597 | 7/20 | 0.33 |
| ▸ | JAK3 | P52333 | 7/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20957919 | 0.90 | KDM5B (0.43) | KDM5BKDM5ANPC1TSHRHSD17B10 | |
| SCHEMBL20958031 | 0.89 | KDM5B (0.46) | KDM5BKDM5AJAK2JAK1TYK2 | |
| SCHEMBL20957957 | 0.88 | KDM5B (0.45) | KDM5BKDM5AJAK2MAPK1JAK1 | |
| SCHEMBL20958016 | 0.88 | KDM5B (0.47) | KDM5BKDM5AJAK2JAK1TYK2 | |
| SCHEMBL20564478 | 0.86 | KDM5B (0.37) | KDM5BKDM5AJAK2JAK1TYK2 | |
| SCHEMBL20957983 | 0.86 | KDM5B (0.52) | KDM5BMAPK1NPC1TSHRHSD17B10 | |
| SCHEMBL20957922 | 0.86 | JAK2 (0.41) | KDM5BJAK2MAPK1JAK1TYK2 | |
| SCHEMBL20957925 | 0.85 | KDM5B (0.48) | KDM5BKDM5A | |
| SCHEMBL20565455 | 0.85 | KDM5B (0.36) | KDM5BKDM5AJAK2JAK1TYK2 | |
| SCHEMBL20957909 | 0.84 | KDM5B (0.41) | KDM5BKDM5AJAK2MAPK1JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | KDM5A, KDM5B, KDM5C | KDM5B 2/4885KDM5A 1/4885JAK2 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.